Sakari Simula
YOU?
Author Swipe
View article: AI-driven MRI analysis reveals brain atrophy patterns in benign relapsing-remitting multiple sclerosis
AI-driven MRI analysis reveals brain atrophy patterns in benign relapsing-remitting multiple sclerosis Open
Background The existence and definition of benign multiple sclerosis (MS) remain controversial, particularly given the discrepancy between clinical presentation and underlying imaging changes. In this study, we aimed to investigate the bra…
View article: Fatigue and health-related quality of life depend on the disability status and clinical course in RRMS
Fatigue and health-related quality of life depend on the disability status and clinical course in RRMS Open
Individuals with severe RRMS and higher EDSS scores are more prone to experience fatigue and lower HRQoL. In addition, fatigue and lower HRQoL are more commonly observed among RRMS patients with older age at disease onset and in those with…
View article: Grey matter atrophy in patients with benign multiple sclerosis
Grey matter atrophy in patients with benign multiple sclerosis Open
Background Brain atrophy appears during the progression of multiple sclerosis (MS) and is associated with the disability caused by the disease. Methods We investigated global and regional grey matter (GM) and white matter (WM) volumes, WM …
View article: Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients Open
View article: Corrigendum to “Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation” [Multiple Sclerosis and Related Disorders 38 (2020) 101498]
Corrigendum to “Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation” [Multiple Sclerosis and Related Disorders 38 (2020) 101498] Open
View article: Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation
Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation Open
View article: Cardiac repolarization during fingolimod treatment in patients with relapsing–remitting multiple sclerosis
Cardiac repolarization during fingolimod treatment in patients with relapsing–remitting multiple sclerosis Open
Background Fingolimod is a sphingosine‐1‐phosphate receptor modulator for the treatment of relapsing–remitting multiple sclerosis ( RRMS ). Despite an established effect on heart rate, the effect of fingolimod on cardiac repolarization is …
View article: The impact of multiple sclerosis onset symptom on cardiac repolarization
The impact of multiple sclerosis onset symptom on cardiac repolarization Open
Introduction Multiple sclerosis is associated with prolonged cardiac repolarization but the underlying physiology has remained unknown. In this study, we compared cardiac repolarization during the relapsing‐remitting multiple sclerosis ( R…
View article: Sequence of cardiovascular autonomic alterations after fingolimod initiation
Sequence of cardiovascular autonomic alterations after fingolimod initiation Open
Background Homeostasis between heart rate and blood pressure is based on several interacting regulatory reflexes, which become influenced by fingolimod initiation. The aim of this study was to determine the sequence of changes in cardiovas…
View article: Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation
Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation Open
Fingolimod is an oral sphingosine-1-phospate (S1P) receptor modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS). In addition to therapeutic effects on lymphoid and neural tissue, fingolimod influences cardiovascula…